Optimized DNA sequence ¬†encoding ¬†extracellular domain of Human Sclerostin (GLN24 - TYR213)¬†including a N-terminal His tag¬†was expressed in HEK293 cells.¬†
Recombinant¬†SOST is a ¬†protein consisting of 195 amino acid residue subunits, ¬†due to glycosylation migrates as an approximately 35kDa protein on SDS-PAGE.
>95%, as determined by SDS-PAGE and HPLC
Endotoxin content was assayed using a LAL gel clot method.
Endotoxin level was found to be less than 0.1 ng/¬Ķg(1EU/¬Ķg).
Recombinant Human Sclerostin is lyophilized ¬†from 0.2 őľm filtered PBS solution, ¬†pH7.2 , ¬†5% Trehalose.
¬†¬† ¬† ¬† ¬† ¬† ¬† ¬†
Recombinant¬†Sclerostin¬†can be stored in working aliquots at 2¬į - 8¬į C for one month, or at -20¬įC to¬†-70¬įC¬†for twelve months.
Avoid repeated freeze/thaw cycles.
This product is for research purposes only.It may not be used for therapeutics or diagnostic purposes.
Sclerostin is an endogenous
antagonist secreted almost
always exclusively by
osteocytes, and it has been
extensively studied as a
major regulator of canonical
Wnt pathway in bone
Sclerostin, an osteocyte-
derived, secreted, cystine-
knot protein inhibits bone
formation by interacting
with and altering the
activity of bone
protein 5 (LRP 5/6),
cysteine-rich protein 61,
the receptor tyrosine kinase
leukemia viral oncogene
homolog 3 (erb B3), among
mutations in the human
sclerostin gene (SOST) are
sclerosteosis or van Buchem
disease both of which are
characterized by progressive
overgrowth and sclerosis of
the axial and appendicular
skeleton and an increase in
bone mineral density
effect of supplemental vitamin d and calcium on serum sclerostin levels
Eur. J. Endocrinol.,
the relationship between inhibitors of the wnt signalling pathway (sclerostin and dickkopf-1) and carotid intima-media thickness in postmenopausal women with type 2 diabetes mellitus
Diabetes and Vascular Disease Research,
48 - 52.
sclerostin: another bone-related protein related to all-cause mortality in haemodialysis?
Nephrol. Dial. Transplant.,
3024 - 3030.
role of sclerostin in bone and cartilage and its potential as a therapeutic target in bone diseases
Therapeutic Advances in Musculoskeletal Diseases,
sclerostin inhibition reverses skeletal fragility in an lrp5-deficient mouse model of oppg syndrome
Science Translational Medicine,